AIM ImmunoTech officers Equels and Rodino voluntarily forego 2024 cash bonuses to fund Ampligen R&D

AIM ImmunoTech Inc.

CEO Thomas K. Equels and Peter W. Rodino III notified the Compensation Committee they will forgo their 2024 cash bonuses.
The voluntary waiver is intended to help AIM focus financial resources on Ampligen R&D activities.
The Compensation Committee then determined that neither will receive a cash bonus for 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.